FTC Extends Scrutiny Of Bristol-Myers' $74B Celgene Buy
Bristol-Myers Squibb Co. and Celgene Corp. said Tuesday that the Federal Trade Commission will take a deeper look at both companies' psoriasis drug portfolios after an initial review of their planned...To view the full article, register now.
Already a subscriber? Click here to view full article